Recently, AccuMedical Inc. (hereinafter referred to as “AccuMedical”) was officially recognized as a Beijing Intellectual Property Advantage Unit by the Beijing Intellectual Property Office, in light of its outstanding performance in intellectual property creation, utilization, management, and protection. This authoritative recognition signifies that AccuMedical’s innovative capabilities and systematic intellectual property strategy in the field of neurointervention have received high-level official acknowledgment.
As an innovative medical device enterprise in neurointervention, AccuMedical has always regarded technological innovation as its core engine for development. By integrating top-tier interdisciplinary teams, the company has established a comprehensive R&D system, overcoming and mastering the core design, development, and manufacturing technologies of neurointerventional devices, while independently researching and developing multiple core technologies. To date, the company has applied for 157 domestic and international patents, building a solid technological barrier.
AccuMedical’s core product, the Lattice® Flow Diverter, embodies the company’s innovation capabilities. Recognized by the NMPA as an Innovative Medical Device, the product leverages original designs such as a mechanical balloon delivery system and MIROR surface modification technology, achieving breakthroughs in effectiveness, safety, and procedural convenience, and breaking away from the long-standing “follow-and-copy” path of domestic enterprises.
From being recognized in 2022 as a Beijing Intellectual Property Pilot Unit to the current upgrade as a Beijing Intellectual Property Advantage Unit, AccuMedical will benefit from enhanced policy support and resource prioritization, facilitating faster translation and application of technological achievements. AccuMedical will continue to deepen its intellectual property strategy, empowering product innovation with high-value patents, and providing better diagnostic and therapeutic solutions for neurovascular patients and physicians worldwide.